Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

Using AI to cure ailments: UK-based BenevolentAI collaborates with AstraZeneca to hasten drug discovery

Editorial team by Editorial team
May 2, 2019
in Startups, Health & Medtech, News, Software & SaaS
0
Using AI to cure ailments: UK-based BenevolentAI collaborates with AstraZeneca to hasten drug discovery
35
SHARES
LinkedInTwitterWhatsAppFacebook

Artificial Intelligence (AI) is being used for a myriad of applications and healthcare is one such prominent field where it’s applied. While there are numerous companies that employ AI to solve varying problems, the rapidly growing UK-based startup BenevolentAI is one step ahead of the lot.

The company was founded in 2013 with the aim of digging deep into data to find insights and solutions, and to apply them to “to transform the way medicines are discovered, developed, tested and brought to market.”

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

BenevolentAI has now made a long-term collaboration with AstraZeneca, a US based global pharmaceutical company. The two organisations will employ machine learning and AI for discovery and development of potential new drugs, for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). Here’s how this new partnership aims to accelerate drug discovery and development.

Amalgamating AI with human experience

With this partnership, scientists from BenevolentAI and AstraZeneca will work together. They will use BenevolentAI target identification platform and biomedical knowledge graph and combine it with AstraZeneca’s genomics, chemistry and clinical data. This will enable the machine learning system to analyse data and find insights to understand connections between facts, which were not unknown before.

Additionally, AI-based reasoning is employed to extrapolate previously undiscovered connections. The companies will then together analyse and interpret the results to “understand the underlying mechanisms of these complex diseases and more quickly identify new potential drug targets.”

Joanna Shields, CEO of BenevolentAI, says,“Millions of people today suffer from diseases that have no effective treatment. The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.”

CKD and IPF are complicated diseases in which the underlying disease biology is said to be poorly understood. Therefore, this disease complexity is said to require the interrogation of vast, rich datasets. This partnership thus will help discover more about the diseases and hopefully, improve the chances of developing treatments for them.

Stay tuned to Silicon Canals for more updates in the tech startup world.

Scaling up in Europe: 5 do’s and don’ts of doing business in the Netherlands

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Hiring during COVID Intrinsic Search
Hiring SaaS sales executives
Check out the do's and don'ts while hiring SaaS sales executives
Check out the do's and don'ts while hiring SaaS sales executives Show Less
Read more
Tags: healthtechstart-up
Share2Tweet9SendShare14

Partner content | Work with us

Future of coding: CTOs discuss low-code versus custom code software development for their business

Why now is the perfect time to start hiring for 2021

SaaS sales in 2021: 9 predictions from an industry expert

Diversity in hiring for SaaS: the often overlooked topic of ageism

Boost your scale-up’s growth by outsourcing to these top Eastern European software development companies

Subscribe to our daily newsletter

Check your inbox or spam folder to confirm your subscription.

Breaking news from Amsterdam | Partner

Meet the 10 Dutch scaleups selected by Amsterdam-based Techleap.nl for Rise Programme 2021

Amsterdam-based 3D Hubs acquired by Protolabs for €272.1M; here’s what you need to know

Amsterdam-based INKEF Capital leads €5M Series A funding round of this Dutch startup

4 experts predict what 2021 might hold for the startup ecosystem of Amsterdam

Advertisement

Trending

3D Hubs
Amsterdam

Amsterdam-based 3D Hubs acquired by Protolabs for €272.1M; here’s what you need to know

January 19, 2021
Amsterdam
Amsterdam

9 promising sustainable startups from Amsterdam to watch in 2021

January 20, 2021
Dutch Scaleup
Amsterdam

Meet the 10 Dutch scaleups selected by Amsterdam-based Techleap.nl for Rise Programme 2021

January 20, 2021
  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info